NASDAQ · BNTX
Healthcare · Biotechnology
$98.00
Up+$2.87 (+2.93%)
Updated Sep 22, 2026, 10:52 PM
SID Score
5.2/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BNTX closed at $98.00 after 20 trading sessions, down 13.14% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 21, 2026 | $97.245 | $98.98 | $96.61 | $98.00 | 801.21K |
| Sep 18, 2026 | $98.81 | $99.25 | $95.71 | $96.06 | 1.2M |
| Sep 17, 2026 | $97.50 | $99.575 | $97.1285 | $98.66 | 708.5K |
| Sep 16, 2026 | $97.24 | $97.32 | $95.315 | $95.83 | 407.6K |
| Sep 15, 2026 | $97.04 | $97.66 | $95.80 | $96.69 | 590.9K |
| Sep 14, 2026 | $102.01 | $103.00 | $97.95 | $98.86 | 1.22M |
| Sep 11, 2026 | $96.77 | $97.90 | $96.00 | $96.73 | 1.18M |
| Sep 10, 2026 | $97.50 | $97.50 | $95.85 | $96.40 | 773.74K |
| Sep 9, 2026 | $98.50 | $98.635 | $96.87 | $98.13 | 707.3K |
| Sep 8, 2026 | $100.24 | $101.33 | $98.18 | $98.66 | 1.13M |
| Sep 4, 2026 | $102.78 | $104.82 | $102.325 | $103.76 | 626.06K |
| Sep 3, 2026 | $104.55 | $105.15 | $102.25 | $102.88 | 1.18M |
| Sep 2, 2026 | $103.24 | $105.4571 | $102.51 | $103.81 | 753.65K |
| Sep 1, 2026 | $100.98 | $102.14 | $100.295 | $101.945 | 1.04M |
| Aug 31, 2026 | $102.01 | $103.00 | $100.8391 | $101.61 | 1.09M |
| Aug 28, 2026 | $102.34 | $105.23 | $98.80 | $102.075 | 3.07M |
| Aug 27, 2026 | $111.69 | $112.81 | $110.25 | $111.40 | 1.55M |
| Aug 26, 2026 | $112.91 | $113.97 | $111.215 | $112.56 | 1.26M |
| Aug 25, 2026 | $113.88 | $116.87 | $113.405 | $114.05 | 1.36M |
| Aug 24, 2026 | $114.03 | $114.195 | $110.517 | $112.82 | 1.85M |
The latest Smart Investors Daily articles mentioning BNTX.
BNTX research
Company profile and research snapshot.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2026 | BMO Capital | Market Perform | — |
| Aug 31, 2026 | Canaccord Genuity | Buy | — |
| Aug 5, 2026 | Evercore ISI Group | Outperform | — |
| Aug 5, 2026 | Citigroup | Buy | — |
| Jul 8, 2026 | Morgan Stanley | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 17, 2026
Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's continued surge, and the one clue hiding in a quiet peer stock reveals exactly what kind of bet the market is actually making.
Yahoo · Sep 16, 2026
BioNTech has been in focus again after fresh clinical trial results, yet the long slide in the share price keeps pulling attention back to a simple question about what investors are paying for its sales. With the stock well below where it traded several years ago, the issue is whether today’s valuation rests on a solid revenue base or on expectations that are hard to pin down. Over the past 5 years the share price has fallen 71.5%, which puts the spotlight firmly on whether the current...
Yahoo · Sep 16, 2026
BioNTech (NasdaqGS:BNTX) moved after fresh clinical news, as investors reacted to detailed Phase 3 data showing its investigational lung cancer therapy gotistobart nearly doubled median overall survival compared with standard chemotherapy. At around US$96.69 per share, BioNTech has seen a 30 day share price return of 3.87% and a 90 day share price return of 4.85%, while the 1 year total shareholder return declined 2.59% and the 5 year total shareholder return fell 71.40%. This suggests that...
Yahoo · Sep 15, 2026
BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BNTX.
